Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

376 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.
Dupuis-Girod S, Ginon I, Saurin JC, Marion D, Guillot E, Decullier E, Roux A, Carette MF, Gilbert-Dussardier B, Hatron PY, Lacombe P, Lorcerie B, Rivière S, Corre R, Giraud S, Bailly S, Paintaud G, Ternant D, Valette PJ, Plauchu H, Faure F. Dupuis-Girod S, et al. Among authors: bailly s. JAMA. 2012 Mar 7;307(9):948-55. doi: 10.1001/jama.2012.250. JAMA. 2012. PMID: 22396517 Clinical Trial.
Bone morphogenetic protein-9 is a circulating vascular quiescence factor.
David L, Mallet C, Keramidas M, Lamandé N, Gasc JM, Dupuis-Girod S, Plauchu H, Feige JJ, Bailly S. David L, et al. Among authors: bailly s. Circ Res. 2008 Apr 25;102(8):914-22. doi: 10.1161/CIRCRESAHA.107.165530. Epub 2008 Feb 28. Circ Res. 2008. PMID: 18309101 Free PMC article.
[Rendu-Osler disease: clinical and molecular update].
Bailly S, Dupuis-Girod S, Plauchu H. Bailly S, et al. Med Sci (Paris). 2010 Oct;26(10):855-60. doi: 10.1051/medsci/20102610855. Med Sci (Paris). 2010. PMID: 20929677 Free article. Review. French.
Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.
Azzopardi N, Dupuis-Girod S, Ternant D, Fargeton AE, Ginon I, Faure F, Decullier E, Roux A, Carette MF, Gilbert-Dussardier B, Hatron PY, Lacombe P, Leguy-Seguin V, Rivière S, Corre R, Bailly S, Paintaud G. Azzopardi N, et al. Among authors: bailly s. MAbs. 2015;7(3):630-7. doi: 10.1080/19420862.2015.1022693. MAbs. 2015. PMID: 25751241 Free PMC article.
Future treatments for hereditary hemorrhagic telangiectasia.
Robert F, Desroches-Castan A, Bailly S, Dupuis-Girod S, Feige JJ. Robert F, et al. Among authors: bailly s. Orphanet J Rare Dis. 2020 Jan 7;15(1):4. doi: 10.1186/s13023-019-1281-4. Orphanet J Rare Dis. 2020. PMID: 31910860 Free PMC article. Review.
Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial.
Dupuis-Girod S, Fargeton AE, Grobost V, Rivière S, Beaudoin M, Decullier E, Bernard L, Bréant V, Colombet B, Philouze P, Bailly S, Faure F, Hermann R. Dupuis-Girod S, et al. Among authors: bailly s. J Clin Med. 2020 Apr 26;9(5):1262. doi: 10.3390/jcm9051262. J Clin Med. 2020. PMID: 32357559 Free PMC article.
Impact of heterozygous ALK1 mutations on the transcriptomic response to BMP9 and BMP10 in endothelial cells from hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension donors.
Al Tabosh T, Liu H, Koça D, Al Tarrass M, Tu L, Giraud S, Delagrange L, Beaudoin M, Rivière S, Grobost V, Rondeau-Lutz M, Dupuis O, Ricard N, Tillet E, Machillot P, Salomon A, Picart C, Battail C, Dupuis-Girod S, Guignabert C, Desroches-Castan A, Bailly S. Al Tabosh T, et al. Among authors: bailly s. Angiogenesis. 2024 May;27(2):211-227. doi: 10.1007/s10456-023-09902-8. Epub 2024 Jan 31. Angiogenesis. 2024. PMID: 38294582 Free PMC article.
376 results